Cytokine pathways involving Interleukin-4 and Interleukin-1 beta (IL-4/IL-1β pathways)

Cytokine pathways involving Interleukin-4 (IL-4) and Interleukin-1 beta (IL-1β) represent two distinct but critical arms of the immune system. Interleukin-4 is a pleiotropic cytokine that induces the differentiation of naive helper T cells into Th2 cells and stimulates B-cell proliferation and class switching to IgE (Source: UniProt P05112). Interleukin-1 beta is a member of the interleukin-1 family and is a crucial mediator of the inflammatory response, involved in cell proliferation, differentiation, and apoptosis (Source: UniProt P01584). The IL-4 pathway is a primary driver of atopic diseases such as asthma and atopic dermatitis, whereas the IL-1β pathway is central to the pathogenesis of autoinflammatory diseases and chronic inflammation (Source: PubMed PMID: 28436958). Therapeutic strategies include the use of Dupilumab to block the IL-4 receptor alpha subunit and agents like Canakinumab or Anakinra to neutralize IL-1β or its receptor (Source: FDA Label for Dupixent and Ilaris). Clinical management of these pathways is essential in treating a wide range of allergic and systemic inflammatory disorders (Source: StatPearls).

Other names

IL-4/IL-1β signalingInterleukin-4 and Interleukin-1 beta axisTh2 and pro-inflammatory cytokine pathways

The mechanism of action involves the pharmacological inhibition of cytokine signaling by either neutralizing the cytokine ligands (e.g., Canakinumab for IL-1β) or blocking their respective receptors (e.g., Dupilumab for IL-4Rα and Anakinra for IL-1R1) to prevent downstream signal transduction (Source: Nature Reviews Drug Discovery).